Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co‐administered with tacrolimus
- 29 December 2018
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (4) , 746-761
Abstract
Aims: Various mycophenolate mofetil (MMF) population pharmacokinetic (popPK) models have been developed to describe its PK characteristics and facilitate its optimal dosing in adult kidney transplant recipients co‐administered with tacrolimus. However, the external predictive performance has been unclear. Thus, this study aimed to comprehensively evaluate the external predictability of published MMF popPK models in such populations and investigate the potential influencing factors.Methods: The external predictability of qualified popPK models was evaluated using an independent dataset. The evaluation included prediction‐ and simulation‐based diagnostics, and Bayesian forecasting. In addition, factors influencing model predictability, especially the impact of structural models, were investigated.Results: Fifty full PK profiles from 45 patients were included in the evaluation dataset and 11 published popPK models were identified and evaluated. In prediction‐based diagnostics, the prediction error within ±30% was less than 50% in most published models. The prediction‐ and variability‐corrected visual predictive check and posterior predictive check showed large discrepancies between the observations and simulations in most models. Moreover, the normalized prediction distribution errors of all models did not follow a normal distribution. Bayesian forecasting demonstrated an improvement in the model predictability. Furthermore, the predictive performance of two‐compartment (2CMT) models incorporating the enterohepatic circulation (EHC) process was not superior to that of conventional 2CMT models.Conclusions: The published models showed large variability and unsatisfactory predictive performance, which indicated that therapeutic drug monitoring was necessary for MMF clinical application. Further studies incorporating potential covariates need to be conducted to investigate the key factors influencing model predictability of MMF.Keywords
Funding Information
- Foundation of Shanghai Municipal Commission of Health and Family Planning
- China Postdoctoral Science Foundation (2017 M622874)
- National Natural Science Foundation of China (81670680, 81573505, 81700655)
- Science and Technology Commission of Shanghai Municipality (2016ZB0301-01)
This publication has 50 references indexed in Scilit:
- Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant RecipientsClinical Pharmacokinetics, 2012
- Nonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid ExposureClinical Journal of the American Society of Nephrology, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune DiseaseClinical Pharmacokinetics, 2011
- Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipientsJournal of Pharmacokinetics and Pharmacodynamics, 2009
- Time‐dependent clearance of mycophenolic acid in renal transplant recipientsBritish Journal of Clinical Pharmacology, 2007
- Methods To Evaluate Biliary Excretion of Drugs in Humans: An Updated ReviewMolecular Pharmaceutics, 2006
- Enterohepatic CirculationClinical Pharmacokinetics, 2002
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981